Pancreatic Cancer Research

ResearcherUNSW SydneyActive in the last 2 years

Minoti Vivek Apte

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0194-8939; OpenAlex author ID A5079752841, A5158663453. Sources: OpenAlex.

Their work

Papers
40 (first author 2, last author 20)
Trials
0
Grants
0
Labs led
1
Collaborators
111
Papers, trials and grants by year

2011: 2 papers · 2012: 2 papers · 2013: 1 paper · 2014: 3 papers · 2015: 1 paper · 2016: 4 papers · 2017: 2 papers · 2018: none · 2019: 1 paper · 2020: 5 papers · 2021: 5 papers · 2022: 3 papers · 2023: 2 papers · 2024: 1 paper · 2025: 2 papers · 2026: 6 papers

Papers 40

  1. Lipid cargo of exosomes derived from pancreatic stellate cells and cancer cells: Role in pancreatic cancer-related diabetes. Co-author DOI 10.1016/j.bbalip.2026.159736↗
  2. Absolute risk of pancreatic cancer in people with acute pancreatitis - theAustralian experience. Co-author DOI 10.1016/j.hpb.2026.05.011↗
  3. Pancreatic cancer cell and stellate cell-derived exosome crosstalk mediates pancreatic cancer-related diabetes. Last author DOI 10.1016/j.pan.2026.10.015↗
  4. HSP47 is a potential dual cell target and prognostic factor in pancreatic cancer. Co-author DOI 10.1038/s41388-026-03865-y↗
  5. Pancreatic cancer. First author DOI 10.1038/s41572-026-00699-6↗
  6. Selective Urokinase Inhibition Plus Chemotherapy: A Novel Approach to Pancreatic Cancer Treatment via Enhanced Antitumor Immunity and Decreased Metastasis. Last author DOI 10.1053/j.gastro.2025.07.021↗
  7. Spatial profiling of endoplasmic reticulum stress markers in tumor associated cells predicts patient outcomes in pancreatic cancer. Co-author DOI 10.1016/j.neo.2024.101115↗
  8. PDAC: advances in tumour microenvironment, microbiome and AI. Co-author DOI 10.1038/s41575-024-01030-y↗
  9. Proteomic profiling of small extracellular vesicles derived from mouse pancreatic cancer and stellate cells: Role in pancreatic cancer. Last author DOI 10.1002/pmic.202300067↗
  10. Emerging role of pancreatic stellate cell-derived extracellular vesicles in pancreatic cancer. Last author DOI 10.1016/j.semcancer.2023.05.007↗
  11. Role of Pancreatic Tumour-Derived Exosomes and Their Cargo in Pancreatic Cancer-Related Diabetes. Last author DOI 10.3390/ijms241210203↗
  12. Small extracellular vesicles (exosomes) and their cargo in pancreatic cancer: Key roles in the hallmarks of cancer. Last author DOI 10.1016/j.bbcan.2022.188728↗
  13. Targeting Wnt/tenascin C-mediated cross talk between pancreatic cancer cells and stellate cells via activation of the metastasis suppressor NDRG1. Co-author DOI 10.1016/j.jbc.2022.101608↗
  14. Metastatic phenotype and immunosuppressive tumour microenvironment in pancreatic ductal adenocarcinoma: Key role of the urokinase plasminogen activator (PLAU). Last author DOI 10.3389/fimmu.2022.1060957↗
  15. Circulating tumour cells in pancreatic cancer: A systematic review and meta-analysis of clinicopathological implications. Last author DOI 10.1016/j.pan.2020.11.022↗
  16. Breaking the cycle: Targeting of NDRG1 to inhibit bi-directional oncogenic cross-talk between pancreatic cancer and stroma. Co-author DOI 10.1096/fj.202002279r↗
  17. Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition. Co-author DOI 10.1158/0008-5472.can-20-2496↗
  18. HGF/c-Met Inhibition as Adjuvant Therapy Improves Outcomes in an Orthotopic Mouse Model of Pancreatic Cancer. Last author DOI 10.3390/cancers13112763↗
  19. Role of Pancreatic Stellate Cell-Derived Exosomes in Pancreatic Cancer-Related Diabetes: A Novel Hypothesis. Last author DOI 10.3390/cancers13205224↗
  20. Pancreatic stellate cells: Aiding and abetting pancreatic cancer progression. Last author DOI 10.1016/j.pan.2020.01.003↗
  21. Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis. Last author DOI 10.1038/s41416-020-0782-1↗
  22. Reply letter to comments on: Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and el… Last author DOI 10.1038/s41416-020-1004-6↗
  23. Targeting HGF/c-MET Axis in Pancreatic Cancer. Last author DOI 10.3390/ijms21239170↗
  24. An Orthotopic Resectional Mouse Model of Pancreatic Cancer. Last author DOI 10.3791/61726↗
  25. Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/path.5224↗
  26. Circulating pancreatic stellate (stromal) cells in pancreatic cancer-a fertile area for novel research. Last author DOI 10.1093/carcin/bgx030↗
  27. Targeting the HGF/c-MET pathway: stromal remodelling in pancreatic cancer. Last author DOI 10.18632/oncotarget.20822↗
  28. Key role of pancreatic stellate cells in pancreatic cancer. Last author DOI 10.1016/j.canlet.2015.10.035↗
  29. Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer. Last author DOI 10.1038/bjc.2015.478↗
  30. Pancreatic cancer. Co-author DOI 10.1038/nrdp.2016.22↗
  31. Pancreatic cancer: A multipronged approach to pancreatic cancer treatment. Co-author DOI 10.1038/nrgastro.2016.75↗
  32. Pancreatic cancer: The microenvironment needs attention too! Co-author DOI 10.1016/j.pan.2015.02.013↗
  33. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Co-author DOI 10.1016/j.cell.2014.08.007↗
  34. The role of the hepatocyte growth factor/c-MET pathway in pancreatic stellate cell-endothelial cell interactions: antiangiogenic implications in pancreatic can… Co-author DOI 10.1093/carcin/bgu122↗
  35. Stars and stripes in pancreatic cancer: role of stellate cells and stroma in cancer progression. Last author DOI 10.3389/fphys.2014.00052↗
  36. A starring role for stellate cells in the pancreatic cancer microenvironment. Co-author DOI 10.1053/j.gastro.2012.11.037↗
  37. The burning question: why is smoking a risk factor for pancreatic cancer? First author DOI 10.1016/j.pan.2012.06.002↗
  38. Dangerous liaisons: pancreatic stellate cells and pancreatic cancer cells. Co-author DOI 10.1111/j.1440-1746.2011.07000.x↗
  39. Recruitment and activation of pancreatic stellate cells from the bone marrow in pancreatic cancer: a model of tumor-host interaction. Co-author DOI 10.1371/journal.pone.0026088↗
  40. Retinoid signaling in pancreatic cancer, injury and regeneration. Co-author DOI 10.1371/journal.pone.0029075↗

Closest collaborators

The 25 strongest of 111 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jeremy S. Wilson · 26 shared papers, 2012–2026 · strength 2.96
  2. Zhihong Xu · 19 shared papers, 2014–2026 · strength 2.55
  3. Chamini Jayamali Perera · 10 shared papers, 2020–2026 · strength 2.10
  4. David Goldstein · 15 shared papers, 2014–2026 · strength 1.57
  5. Tony Pang · 8 shared papers, 2017–2026 · strength 1.22
  6. Srinivasa P. Pothula · 12 shared papers, 2014–2021 · strength 1.16
  7. Helen Barong Binang · 3 shared papers, 2023–2026 · strength 0.83
  8. S. M. Zahid Hosen · 4 shared papers, 2022–2026 · strength 0.82
  9. Rohit Sarkar · 3 shared papers, 2023–2026 · strength 0.78
  10. Suresh T. Chari · 3 shared papers, 2021–2026 · strength 0.57
  11. Marie Ranson · 2 shared papers, 2022–2026 · strength 0.39
  12. Georgia Porter · 1 shared paper, 2025 · strength 0.37
  13. Angelica M. Merlot · 1 shared paper, 2025 · strength 0.37
  14. Mert Erkan · 3 shared papers, 2019–2026 · strength 0.36
  15. Marco Falasca · 2 shared papers, 2021–2024 · strength 0.34
  16. Rachel Ε. Neale · 2 shared papers, 2016–2026 · strength 0.32
  17. Val Gebski · 2 shared papers, 2021–2026 · strength 0.29
  18. Joshua A. McCarroll · 2 shared papers, 2021–2026 · strength 0.29
  19. Amber L. Johns · 2 shared papers, 2021–2026 · strength 0.29
  20. Koroush Shahsavar Haghighi · 2 shared papers, 2021–2026 · strength 0.29
  21. Phoebe A. Phillips · 2 shared papers, 2021–2026 · strength 0.29
  22. George Sharbeen · 2 shared papers, 2021–2026 · strength 0.29
  23. Anthony James Gill · 2 shared papers, 2021–2026 · strength 0.29
  24. John Kokkinos · 2 shared papers, 2021–2026 · strength 0.29
  25. Jennifer P. Morton · 2 shared papers, 2021–2026 · strength 0.29

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.